Sexual function in men undergoing androgen deprivation therapy.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
28
08
2020
accepted:
12
02
2021
revised:
13
11
2020
pubmed:
23
3
2021
medline:
21
5
2021
entrez:
22
3
2021
Statut:
ppublish
Résumé
Androgen deprivation therapy (ADT) has a deleterious effect on sexual functions and general well-being in men. Despite this evidence, however, patient and couple knowledge about ADT side effects as well as their management is poor. Similar considerations can be made for physician endorsement of management strategies. In this paper, we summarize and critically discuss available evidence regarding the possible associations between ADT and sexual dysfunction as well as the best therapeutical options. Preclinical data show that ADT is associated with penile contractility impairment as well as lower response to phosphodiesterase type 5 inhibitors (PDE5i). Available data indicate that ADT resulted in a five to sixfold increased risk of reduced libido and in a threefold increased risk of ED confirming the main role of testosterone in regulating sexual desire. Despite this evidence, sexuality remains an important aspect of health and well-being for men and their partner. The best therapeutical options depend on patient and couple desires and needs. When nonpenetrative erections are still possible, nonpenetrative activities should be encouraged to maintain sexual intimacy. A combined and personal educational program including the collaboration of different professional figures (including general physicians, oncologists, andrologists, sexologists, and psychologists) trained in sexual medicine is advisable in order to provide the best support to subjects undergoing ADT.
Identifiants
pubmed: 33746211
doi: 10.1038/s41443-021-00418-7
pii: 10.1038/s41443-021-00418-7
doi:
Substances chimiques
Androgen Antagonists
0
Androgens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
439-447Références
Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. European Association of Urology; https://uroweb.org/guideline/prostate-cancer/ . Accessed 20 Apr 2020.
Corona G, Gacci M, Baldi E, Mancina R, Forti G, Maggi M. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects. J Sex Med. 2012;9:887–902.
Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Investig. 2011;34:232–43.
Corona G, Filippi S, Bianchi N, Dicuio M, Rastrelli G, Concetti S, et al. Cardiovascular risks of androgen deprivation therapy for prostate cancer. World J Men’s Health. 2020. https://doi.org/10.5534/wjmh.200109 .
Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. 2010;121:833–40.
Rastrelli G, Lotti F, Reisman Y, Sforza A, Maggi M, Corona G. Metabolically healthy and unhealthy obesity in erectile dysfunction and male infertility. Expert Rev Endocrinol Metab. 2019;14:321–34.
Lotti F, Rastrelli G, Maseroli E, Cipriani S, Guaraldi F, Krausz C, et al. Impact of metabolically healthy obesity in patients with andrological problems. J Sex Med. 2019;16:821–32.
pubmed: 30962157
doi: 10.1016/j.jsxm.2019.03.006
Grossmann M, Fui MNT, Cheung AS. Late-onset hypogonadism: metabolic impact. Andrology. 2019. https://doi.org/10.1111/andr.12705 .
Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15:1260–71.
Maseroli E, Corona G, Rastrelli G, Lotti F, Cipriani S, Forti G, et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. 2015;12:956–65.
pubmed: 25689116
doi: 10.1111/jsm.12832
Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European Society of Endocrinology. Andrology. 2020. https://doi.org/10.1111/andr.12770 .
Rochira V, Antonio L, Vanderschueren D. EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology. 2018;6:272–85.
pubmed: 29499097
doi: 10.1111/andr.12470
Joseph JS, Lam V, Patel MI. Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2019;2:551–61.
pubmed: 31411986
doi: 10.1016/j.euo.2018.11.001
Rastrelli G, Corona G, Maggi M. Testosterone and sexual function in men. Maturitas. 2018;112:46–52.
pubmed: 29704917
doi: 10.1016/j.maturitas.2018.04.004
Rastrelli G, Guaraldi F, Reismann Y, Sforza A, Isidori AM, Maggi M. et al. Testosterone replacement therapy for sexual symptoms. Sex Med Rev. 2019;7:464–75.
pubmed: 30803919
doi: 10.1016/j.sxmr.2018.11.005
Maggi M, Filippi S, Vignozzi L, Rastrelli G. Controversial aspects of testosterone in the regulation of sexual function in late-onset hypogonadism. Andrology. 2020. https://doi.org/10.1111/andr.12794 .
Corona G, Torres LO, Maggi M. Testosterone therapy: what we have learned from trials. J Sex Med. 2020;17:447–60.
pubmed: 31928918
doi: 10.1016/j.jsxm.2019.11.270
Corona G, Gacci M, Baldi E, Mancina R, Forti G, Maggi M. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects. J Sex Med. 2012;9:887–902.
pubmed: 22248394
doi: 10.1111/j.1743-6109.2011.02590.x
Mazzola CR, Mulhall JP. Impact of androgen deprivation therapy on sexual function. Asian J Androl. 2012;14:198–203.
Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19:3750–7.
pubmed: 11533098
doi: 10.1200/JCO.2001.19.17.3750
Rot I, Wassersug RJ, Walker LM. What do urologists think patients need to know when starting on androgen deprivation therapy? The perspective from Canada versus countries with lower gross domestic product. Transl Androl Urol. 2016;5:235–47.
pubmed: 27141453
pmcid: 4837317
doi: 10.21037/tau.2016.03.06
Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M. Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores. Eur Urol. 2017;72:1000–11.
pubmed: 28434676
doi: 10.1016/j.eururo.2017.03.032
Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11:1577–92.
pubmed: 24697970
doi: 10.1111/jsm.12536
Filippi S, Luconi M, Granchi S, Natali A, Tozzi P, Forti G, et al. Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation. Int J Impot Res. 2002;14:295–307.
pubmed: 12152120
doi: 10.1038/sj.ijir.3900890
Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med. 2009;6:3274–88.
pubmed: 19732305
doi: 10.1111/j.1743-6109.2009.01467.x
Maggi M, Filippi S, Ledda F, Magini A, Forti G. Erectile dysfunction: frombiochemical pharmacology to advances in medical therapy. Eur J Endocrinol. 2000;143:143–54.
pubmed: 10913932
doi: 10.1530/eje.0.1430143
Vignozzi L, Corona G, Petrone L, Filippi S, Morelli AM, Forti G, et al. Testosterone and sexual activity. J Endocrinol Investig. 2005;28:39–44.
Morelli A, Corona G, Filippi S, Ambrosini S, Forti G, Vignozzi L, et al. Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Investig. 2007;30:880–8.
doi: 10.1007/BF03349232
Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65:99–112.
pubmed: 24050791
doi: 10.1016/j.eururo.2013.08.048
Gravina GL, Marampon F, Sanità P, Festuccia C, Forcella C, Scarsella L et al. Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pAR ser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy. Oncotarget. 2017;8:113792–806.
pubmed: 29371946
pmcid: 5768363
doi: 10.18632/oncotarget.22776
Rousseau L, Dupont A, Labrie F, Couture M. Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav. 1988;17:87–98.
pubmed: 3358677
doi: 10.1007/BF01542054
Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. Natl Cancer Inst. 2002;94:430–7.
doi: 10.1093/jnci/94.6.430
Fowler FJ Jr, Collins MM, Corkery EW, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer. 2002;95:287–95.
pubmed: 12124828
doi: 10.1002/cncr.10656
Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer. 2003;97:1653–62.
pubmed: 12655522
doi: 10.1002/cncr.11233
DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, et al. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int. 2008;102:39–43.
Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression. J Urol. 2012;187:2162–6.
Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117:E36–45.
pubmed: 25959859
doi: 10.1111/bju.13179
Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, et al. Functional outcomes and quality of life after radical prostatectomy only versus a combination of prostatectomy with radiation and hormonal therapy. Eur Urol. 2017;71:330–6.
pubmed: 27887941
doi: 10.1016/j.eururo.2016.11.015
Stoleru S, Gregoire MC, Gerard D, Decety J, Lafarge E, Cinotti L, et al. Neuroanatomical correlates of visually evoked sexual arousal in human males. Arch Sex Behav. 1999;28:1–21.
pubmed: 10097801
doi: 10.1023/A:1018733420467
Park K, Seo JJ, Kang HK, Ryu SB, Kim HJ, Jeong GW. A new potential of blood oxygenation level dependent (BOLD) functional MRI for evaluating cerebral centers of penile erection. Int J Impot Res. 2001;13:73–81.
pubmed: 11426342
doi: 10.1038/sj.ijir.3900649
Azad N, Pitale S, Barnes WE, Friedman N. Testosterone treatment enhances regional brain perfusion in hypogonadal men. J Clin Endocrinol Metab. 2003;88:3064–8.
pubmed: 12843144
doi: 10.1210/jc.2002-020632
Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35.
pubmed: 20554979
doi: 10.1056/NEJMoa0911101
Rastrelli G, Corona G, Tarocchi M, Mannucci E, Maggi M. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Investig. 2016;39:473–84.
doi: 10.1007/s40618-015-0425-1
Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015;100:1146–55.
pubmed: 25548978
doi: 10.1210/jc.2014-3818
Dean JD, McMahon GC, Guay AT, Morgentaler A, Althof SE, Becher EF et al. The International Society for Sexual Medicine’s Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. J Sex Med. 2015;12:1660–86.
pubmed: 26081680
doi: 10.1111/jsm.12952
Jannini EA, Nappi RE. Couple pause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med Rev. 2018;6:384–95.
Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. Clin Endocrinol Metab. 1983;57:557–62.
doi: 10.1210/jcem-57-3-557
Fode M, Mosholt KS, Nielsen TK, Tolouee S, Giraldi A, Østergren PB, et al. Sexual motivators and endorsement of models describing sexual response of men undergoing androgen deprivation therapy for advanced prostate cancer. J Sex Med. 2020;17:1538–43.
Walker LM, Robinson JW. Sexual adjustment to androgen deprivation therapy: struggles and strategies. Qual Health Res. 2012;22:452–65.
Corona G, Rastrelli G, Balercia G, Sforza A, Forti G, Mannucci E, et al. Perceived reduced sleep-related erections in subjects with erectile dysfunction: psychobiological correlates. J Sex Med. 2011;8:1780–8.
pubmed: 21426496
doi: 10.1111/j.1743-6109.2011.02241.x
Carosa E, Volpe R, Martini P, Brandetti F, Di Stasi SM, Lombardo F, et al. Psychosocial issues of ART in aging male. J Endocrinol Investig. 2005;28:117–21.
Benedict C, Traeger L, Dahn JR, Antoni M, Zhou ES, Bustillo N, et al. Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy. J Sex Med. 2014;11:2571–80.
pubmed: 25059094
doi: 10.1111/jsm.12645
Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis JAMA Oncol. 2015;1:1261–9.
Bruner DW, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T, et al. Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med. 2011;8:1228–38.
pmcid: 3557497
doi: 10.1111/j.1743-6109.2010.02164.x
Corona G, Rastrelli G, Burri A, Serra E, Gianfrilli D, Mannucci E, et al. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. Andrology. 2016;4:1002–9.
pubmed: 27636710
doi: 10.1111/andr.12255
Schover LR. Sexual healing in patients with prostate cancer on hormone therapy. Am Soc Clin Oncol Educ Book. 2015;e562–6.
Osmonov D, Christopher AN, Blecher GA, Falcone M, Soave A, Dahlem R, et al. Clinical recommendations from the European Society for Sexual Medicine exploring partner expectations, satisfaction in male and phalloplasty cohorts, the impact of penile length, girth and implant type, reservoir placement, and the influence of comorbidities and social circumstances. J Sex Med. 2020;17:210–37.
pubmed: 31812683
doi: 10.1016/j.jsxm.2019.10.016
Capogrosso P, Frey A, Jensen CFS, Rastrelli G, Russo GI, Torremade J, et al. Low-intensity shock wave therapy in sexual medicine-clinical recommendations from the European Society of Sexual Medicine (ESSM). J Sex Med. 2019;16:1490–505.
pubmed: 31447380
doi: 10.1016/j.jsxm.2019.07.016
Schmidt HM, Munder T, Gerger H, Frühauf S, Barth J. Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis. J Sex Med. 2014;11:1376–91.
pubmed: 24641632
doi: 10.1111/jsm.12520
Boddi V, Castellini G, Casale H, Rastrelli G, Boni L, Corona G, et al. An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology. 2015;3:909–18.
pubmed: 26311340
doi: 10.1111/andr.12079
Allen MS, Walter EE. Erectile dysfunction: an umbrella review of meta-analyses of risk-factors, treatment, and prevalence outcomes. J Sex Med. 2019;16:531–41.
Wibowo E, Wassersug RJ, Robinson JW, Santos-Iglesias P, Matthew A, McLeod DL, et al. An educational program to help patients manage androgen deprivation therapy side effects: feasibility, acceptability, and preliminary outcomes. Am J Mens Health. 2020;14:1557988319898991.
pubmed: 32024430
pmcid: 7005977
doi: 10.1177/1557988319898991
Walker LM, Robinson JW. A description of heterosexual couples’ sexual adjustment to androgen deprivation therapy for prostate cancer. Psychooncology. 2011;20:880–8.
pubmed: 20623824
doi: 10.1002/pon.1794
Walker LM, Hampton AJ, Wassersug RJ, Thomas BC, Robinson JW. Androgen deprivation therapy and maintenance of intimacy: a randomized controlled pilot study of an educational intervention for patients and their partners. Contemp Clin Trials. 2013;34:227–31
Wibowo E, Wassersug RJ, Robinson JW, Matthew A, McLeod D, Walker LM. How are patients with prostate cancer managing androgen deprivation therapy side effects? Clin Genitourin Cancer. 2019;17:e408–19.
pubmed: 30745202
doi: 10.1016/j.clgc.2018.12.006